Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Evofem Biosciences, Inc.
Evofem Biosciences, Inc. (EVFM) dilution facts from SEC filings
Snapshot as of Sep 30, 2026, built from 7 SEC filings.
- Shelf registration
- None on file in the filings reviewed
- At-the-market (ATM) program
- No active program in the filings reviewed
- Warrants outstanding
- 15 warrant series recorded as outstanding
- Most recent offering
- None recorded in the filings reviewed
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.